These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12737333)

  • 21. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study.
    Temekonidis TI; Alamanos Y; Nikas SN; Bougias DV; Georgiadis AN; Voulgari PV; Drosos AA
    Ann Rheum Dis; 2003 Dec; 62(12):1218-20. PubMed ID: 14644863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period.
    Braun J; Deodhar A; Dijkmans B; Geusens P; Sieper J; Williamson P; Xu W; Visvanathan S; Baker D; Goldstein N; van der Heijde D;
    Arthritis Rheum; 2008 Sep; 59(9):1270-8. PubMed ID: 18759257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safe re-initiation of infliximab in a patient with renal tuberculosis.
    Kemta Lekpa F; Marini-Portugal A; Lesprit P; Chevalier X; Claudepierre P
    Clin Exp Rheumatol; 2009; 27(3):534. PubMed ID: 19604451
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis.
    Stone M; Salonen D; Lax M; Payne U; Lapp V; Inman R
    J Rheumatol; 2001 Jul; 28(7):1605-14. PubMed ID: 11469469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement.
    Rejón E; Giménez MD; Mayordomo L; Rodríguez S; González MP; Marenco JL
    Scand J Rheumatol; 2004; 33(5):323-6. PubMed ID: 15513681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low dose of infliximab is inadequate in most patients with spondylarthropathies.
    Sidiropoulos P; Kritikos HD; Siakka P; Mamoulaki M; Kouroumali H; Voudouris K; Boumpas DT
    Clin Exp Rheumatol; 2005; 23(4):513-6. PubMed ID: 16095121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of low-dose infliximab on spinal inflammation on magnetic resonance imaging in ankylosing spondylitis.
    Rudwaleit M
    J Rheumatol; 2010 Aug; 37(8):1553-5. PubMed ID: 20675850
    [No Abstract]   [Full Text] [Related]  

  • 28. Measures of outcome in ankylosing spondylitis and other spondyloarthritides.
    van der Heijde DM; van der Linden S
    Baillieres Clin Rheumatol; 1998 Nov; 12(4):683-93. PubMed ID: 9928502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infliximab treatment for rheumatic disease: clinical and radiological efficacy.
    St Clair EW
    Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii67-9. PubMed ID: 12379627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis.
    Romero-Sánchez C; Robinson WH; Tomooka BH; Londoño J; Valle-Oñate R; Huang F; Deng X; Zhang L; Yang C; Yu DT
    Clin Rheumatol; 2008 Nov; 27(11):1429-35. PubMed ID: 18566849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.
    Brandt J; Haibel H; Cornely D; Golder W; Gonzalez J; Reddig J; Thriene W; Sieper J; Braun J
    Arthritis Rheum; 2000 Jun; 43(6):1346-52. PubMed ID: 10857793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
    Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
    Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reactive arthritis of the cervical spine due to Yersinia enterocolitica in a patient with preexisting ankylosing spondylitis.
    Gran JT; Paulsen AQ; Gåskjenn H; Schulz T
    Scand J Rheumatol; 1992; 21(2):95-6. PubMed ID: 1570498
    [No Abstract]   [Full Text] [Related]  

  • 34. Psoriasis, erythema nodosum, and nummular eczema onset in an ankylosing spondylitis patient treated with infliximab.
    Delle Sedie A; Bazzichi L; Bombardieri S; Riente L
    Scand J Rheumatol; 2007; 36(5):403-4. PubMed ID: 17963173
    [No Abstract]   [Full Text] [Related]  

  • 35. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study.
    Marzo-Ortega H; McGonagle D; Jarrett S; Haugeberg G; Hensor E; O'connor P; Tan AL; Conaghan PG; Greenstein A; Emery P
    Ann Rheum Dis; 2005 Nov; 64(11):1568-75. PubMed ID: 15829577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab.
    Braun J; van der Heijde D; Doyle MK; Han C; Deodhar A; Inman R; de Vlam K; Burmester GR; Van den Bosch F; Xu S; Visvanathan S; Rahman MU
    Arthritis Rheum; 2009 Aug; 61(8):1032-6. PubMed ID: 19644896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of reactive arthritis with infliximab].
    Abdelmoula LC; Yahia CB; Testouri N; Tekaya R; Ben M'barek R; Chaabouni L; Zouari R
    Tunis Med; 2008 Dec; 86(12):1095-7. PubMed ID: 19213526
    [No Abstract]   [Full Text] [Related]  

  • 38. Psoriasis onset during infliximab treatment: description of two cases.
    Volpe A; Caramaschi P; Carletto A; Pieropan S; Bambara LM; Biasi D
    Rheumatol Int; 2006 Oct; 26(12):1158-60. PubMed ID: 16738903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A short-term efficacy and safety study of infliximab in active ankylosing spondylitis].
    Huang F; Zhang LY; Zhang JL; Zhang FC; Liang DF; Deng XH; Guo JH; Zhu J; Zhao W; Li XF; Hou Y
    Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):122-6. PubMed ID: 16624120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.